

CURRICULUM VITAE

Roberto Mina, MD

Personal data

Date of birth: August 9, 1987
Place of birth: Savigliano (CN), Italy
Citizenship: Italian
Mailing address: Divisione Universitaria di Ematologia
Via Genova 3, 10126 Torino, Italy
Fax: + 39-011-6336507;
Phone (work): +39-011-633-5878/4555/5504
E-mail: roberto.mina.rm@gmail.com

Albo Provinciale dei Medici Chirurghi di TORINO (Ordine della Provincia di TORINO) n. 0000022724

Education

2012

Medical degree (110/110 with distinction), University of Torino, Italy

2012

Italian Board Examination for M.D. – 2nd session.

2018

Post-graduate degree in Hematology (70/70 with distinction), University of Torino, Italy

Professional records

2012-2013

Internship, Division of Hematology, University of Torino, Italy

8/2013-8/2018

Clinical and Research Fellowship, Hematology division, University of Torino, Italy.

10/2017-6/2018

Visiting scholar at Winship Cancer Institute Department of hematology and medical oncology, Emory University, Atlanta, Georgia (USA)

9/2018- 5/2019

Research fellow, Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy

6/2019- to date

Ricercatore a tempo determinate, Assistant Professor, Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy

Clinical activity

Clinical management of hematological and onco-hematological patients in both the inpatient and outpatient facilities, comprising bone marrow transplantation. Specifically focused on plasma-cell disorders, including multiple myeloma, both patients eligible for autologous stem cell transplant and older patients non transplant-eligible, and monoclonal gammopathies of undetermined significance (MGUS), amyloidosis and rare plasma cell dyscrasias (plasma-cell leukemias, POEMS syndrome).

Editorial activity

- Reviewer for *Annals of Hematology*, *Neoplasma* and *Drugs in R&D*

Spoken languages

Italian: mother tongue

English: Excellent in writing and speaking

Scientific interests

- Diagnosis, clinics and treatment of plasma-cell disorders (Multiple myeloma, plasma-cell leukemia, monoclonal gammopathies of undetermined significance, amyloidosis and POMES syndrome).
- Minimal residual disease assessment in multiple myeloma.
- Biology and genetics of multiple myeloma.
- Autologous stem cell transplantation and novel agents for multiple myeloma.
- Treatment of older adults with multiple myeloma and frailty assessment.
- Design and conduction of clinical trials in plasma-cell disorders, including multiple myeloma and plasma-cell leukemia.

Ongoing projects

Currently actively involved in several national and international clinical trials, mainly focusing on multiple myeloma research.

Over the past years Dr. Mina participated, as a sub-investigator, in several phase Ib, II and III clinical trials in multiple myeloma (43 sponsored studies, 8 non-profit studies), as well as in phase III trials in AL amyloidosis.

Dr. Mina is currently serving as a member of the medical monitoring team of the European Myeloma Network (EMN) in the context of the EMN17/54767414MMY3014 study.

Scientific Production

Official H-index: 9

ORCID ID: 0000-0002-8144-541X

Scopus Author ID: 55382956600

Manuscripts

1. Larocca A, **Mina R**, Offidani M, Liberati AM, Ledda A, Patriarca F, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangialosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, De Paoli L, Romano A, Palumbo A, Montefusco V, Hajek R, Boccadoro M, Bringhen S. First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. *Haematologica*. 2019 Jun 27. pii: haematol.2019.220657. doi: 10.3324/haematol.2019.220657.
2. **Mina R**, Bringhen S, Wildes TM, Zweegman S, Rosko AE. Approach to the Older Adult With Multiple Myeloma. *Am Soc Clin Oncol Educ Book*. 2019 Jan;39:500-518.
3. Gay F, **Mina R**. Redefining the treatment paradigm for multiple myeloma. *Lancet Oncol*. 2019 Jun;20(6):743-744.
4. **Mina R**, Lonial S. Is there still a role for stem cell transplantation in multiple myeloma? *Cancer*. 2019 Aug 1;125(15):2534-2543.
5. Castella B, **Mina R**, Gay F. CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab. *Cytometry A*. 2019 Apr;95(4):416-418. doi: 10.1002/cyto.a.23752.
6. Kaufman JL*, **Mina R***, Jakubowiak AJ, Zimmerman TL, Wolf JJ, Lewis C, Gleason C, Sharp C, Martin T, Heffner LT, Nooka AJ, Harvey RD and Lonial S. * Kaufman JL and Mina R. share the first authorship.
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I study. *Blood Cancer J*. 2019 Jan 4;9(1):3. doi: 10.1038/s41408-018-0154-8. PubMed PMID: 30610196.
7. Bringhen S, **Mina R**, Petrucci MT, Gaidano G, Ballanti S, Musto P, Offidani M, Spada S, Benevolo G, Ponticelli E, Galieni P, Cavo M, Caravita di Toritto T, Di Raimondo F, Montefusco V, Palumbo A, Boccadoro M, Larocca A. Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase 1/2 studies. *Haematologica*. 2019 Feb 7. pii: haematol.2018.208272.
8. **Mina R**, Joseph NS, Kaufman JL, Gupta VA, Heffner LT, Hofmeister CC, Boise LH, Dhodapkar MV, Gleason C, Nooka AK, Lonial S.

Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer. 2018 Oct 17. doi: 10.1002/cncr.31718. [Epub ahead of print]

9. **Mina R**, Petrucci MT, Corradini P, Spada S, Patriarca F, Cerrato C, De Paoli L, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, Hajek R, Spencer A, Boccadoro R, Bringhen S.
Treatment intensification with autologous stem cell transplantation and lenalidomide maintenance improves survival outcomes of patients with newly diagnosed multiple myeloma in complete response. Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8): 533-540.
10. Cerrato C, Di Raimondo F, De Paoli L, Spada S, Patriarca F, Crippa C, **Mina R**, Guglielmelli T, Ben-Yehuda D, Oddolo D, Nozzoli C, Angelucci E, Cascavilla R, Rizzi R, Rocco S, Baldini L, Ponticelli E, Marcatti M, Cangialosi C, Caravita T, Benevolo G, Ria R, Nagler A, Musto P, Tacchetti P, Corradini P, Offidani M, Palumbo A, Petrucci MT, Boccadoro M, Gay F.
Maintenance in myeloma patients achieving complete response after upfront therapy: pooled analysis. J Cancer Res Clin Oncol. 2018 Jul; 144(7): 1357-1366
11. Bringhen S, **Mina R**, Cafro AM, Liberati AM, Spada S, Belotti A, Gaidano G, Patriarca F, Troia R, Fanin R, De Paoli L, Rossi G, Lombardo A, Bertazzoni P, Palumbo A, Sonneveld P, Boccadoro M.
Once-weekly carfilzomib, pomalidomide and low-dose dexamethasone for relapsed/refractory myeloma: a phase II study. Leukemia. 2018 Jan 30
12. Larocca A, **Mina R**, Gay F, Bringhen S, Boccadoro M.
Emerging drugs and combinations to treat multiple myeloma. Oncotarget. 2017 Jul 15;8(36):60656-60672.
13. **Mina R**, D'Agostino M, Cerrato C, Gay F, Palumbo A.
Plasma cell leukemia: update on biology and therapy. Leuk Lymphoma. 2016 Nov 6:1-10.
14. Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, **Mina R**, Falcone AP, De Paoli L, Pietrantuono G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A.
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016 Mar 3;127(9):1102-8.
15. **Mina R**, Cerrato C, Bernardini A, Aghemo E, Palumbo A.
New pharmacotherapy options for multiple myeloma. Expert Opin Pharmacother. 2016;17(2):181-92.
16. Bringhen S, Gay F, Donato F, Troia R, **Mina R**, Palumbo A.
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma. Expert Opin Investig Drugs. 2014 Sep;23(9):1193-209.
17. Ozaki S, Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H, Kuroda Y, Chou T, Yoshiki Y, Suzuki K, Murakami H, Hayashi K, **Mina R**, Palumbo A, Shimizu K; Japanese Society of Myeloma.; European Myeloma Network.
Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the

Japanese Society of Myeloma and the European Myeloma Network. Acta Haematol. 2014;132(2):211-9.

18. Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omedé P, Marasca R, Morabito F, **Mina R**, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M.
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. *J Clin Oncol.* 2014 Mar 1;32(7):634-40.
19. Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, **Mina R**, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omedè P, Lerosé R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A.
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. *Leukemia.* 2014 Jan;28(1):222-5.
20. Cerrato C, **Mina R**, Palumbo A.
Optimal management of elderly patients with myeloma. *Expert Rev Anticancer Ther.* 2014 Feb;14(2):217-28
21. Palumbo A, **Mina R**, Cerrato C, Cavallo F.
Role of consolidation/maintenance therapy in multiple myeloma. *Clin Lymphoma Myeloma Leuk.* 2013
22. Gay F, **Mina R**, Troia R, Bringhen S.
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. *Expert Opin Drug Metab Toxicol.* 2013 Nov;9(11):1517-27.
23. Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, **Mina R**, Galli M, Marcatti M, La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omedé P, Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A.
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. *Blood.* 2013 Oct17;122(16):2799-806.
24. Palumbo A, **Mina R**.
Management of older adults with multiple myeloma. *Blood Rev.* 2013 May;27(3):133-42
25. Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D, Cavalli M, Wijermans P, Ria R, Offidani M, Lahuerta JJ, Liberati AM, **Mina R**, Callea V, Schaafsma M, Cerrato C, Marasca R, Franceschini L, Evangelista A, Teruel AI, van der Holt B, Montefusco V, Ciccone G, Boccadoro M, San Miguel J, Sonneveld P, Palumbo A.
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. *Haematologica.* 2013 Jun;98(6):980-7.
26. Palumbo A, **Mina R**.
Part II: role of maintenance therapy in transplant-ineligible patients. *J Natl Compr Canc Netw.* 2013 Jan 1;11(1):43-9. Review.
27. Larocca A, Cavallo F, **Mina R**, Boccadoro M, Palumbo A.

Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. Future Oncol. 2012 Oct;8(10):1223-38

28. Falco P, Cavallo F, Larocca A, Rossi D, Guglielmelli T, Rocci A, Grasso M, Siez ML, De Paoli L, Oliva S, Molica S, **Mina R**, Gay F, Benevolo G, Musto P, Omedè P, Freilone R, Bringhen S, Carella AM, Gaidano G, Boccadoro M, Palumbo A.
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia. 2013 Mar;27(3):695-701.

Abstracts

1. **Roberto Mina**, Alessandra Larocca, MariaTeresa Petrucci, Gianluca Gaidano, Stelvio Ballanti, Pellegrino Musto, Massimo Offidani, Paola Omedé, Giulia Benevolo, Alessandra Malfitano, Piero Galieni, Michele Cavo, Tommaso Caravita di Toritto, Vittorio Del Fabro, Vittorio Montefusco, Antonio Palumbo, Mario Boccadoro and Sara Bringhen.
Long-Term Carfilzomib for High-Risk Patients with Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies. Blood 2018 132:3240. ASH 2018
2. Sara Bringhen, **Roberto Mina**, Maria Teresa Petrucci, Lorenzo De Paoli, Stelvio Ballanti, Pellegrino Musto, Massimo Offidani, Stefano Spada, Giulia Benevolo, Elena Ponticelli, Piero Galieni, Michele Cavo, Tommaso Caravita di Toritto, Concetta Conticello, Vittorio Montefusco, Antonio Palumbo, Mario Boccadoro and Alessandra Larocca.
Once Weekly Versus Twice Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies. Blood 2018 132:1990
3. **Roberto Mina**, Nisha Joseph, Francesca Gay, Ajay Nooka, Efstathios Kastritis, Stefano Spada, Maria Teresa Petrucci, Jonathan L. Kaufman, Vittorio Montefusco, Maria Gavriatopoulous, Francesca Patriarca, Milena Gilestro, Lawrence H. Boise, Concetta Conticello, Sonia Grandi, Maria Roussou, Nicola Giuliani, Anna Marina Liberati, Dhvani Almaula, Massimo Offidani, Rossella Ribolla, David L. Jaye, Lorenzo De Paoli, Evangelos Terpos, Sagar Lonial, Mario Boccadoro, Meletios A. Dimopoulos.
Translocation (14;16) Positive Multiple Myeloma Patients: Clinical Features And Survival Outcomes Of A High-Risk Population. Jun 15, 2018; 215039. EHA 2018
4. **Roberto Mina**, Alessandra Larocca, Angelo Belotti, Francesco Di Raimondo, Anna Baraldi, Massimo Offidani, Monia Marchetti, Roberto Ria, Annarita Conconi, Norbert Pescosta, Mariella Grasso, Giusy Cetani, Anna Maria Cafro, Roberto Passera, Rossella Troia, Gianpietro Semenzato, Nicola Giuliani, Stelvio Ballanti, Claudia Cellini, Anna Marina Liberati, Tommaso Caravita di Toritto, Maria Teresa Petrucci, Pellegrino Musto, Antonio Palumbo, Pieter Sonneveld and Mario Boccadoro.
Bortezomib-Dexamethasone Re-Treatment at Biochemical Relapse Vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II Multi-Center, Randomized Study. Blood 2017 130:3128; ASH 2017
5. Sara Bringhen, **Roberto Mina**, Maria Teresa Petrucci, Nicola Giuliani, Emanuele Angelucci, Mariella Genuardi, Tommaso Caravita di Toritto, Alessandra Malfitano, Pellegrino Musto,

Roberto Ria, Giovannino Ciccone, Elona Saraci, Massimo Offidani, Caterina Musolino, Rossella Troia, Anna Marina Liberati, Lorenzo De Paoli, Stelvio Ballanti, Fabrizio Esma, Piero Galieni, Michele Cavo, Concetta Conticello, Renato Zambello, Paolo Corradini, Giulia Benevolo, Antonio Palumbo, Pieter Sonneveld, Mario Boccardo

Incidence and risk factors of cardiovascular adverse events in a large population of newly-diagnosed, transplant ineligible myeloma patients treated with carfilzomib. May 18, 2017; 181023. EHA 2017

6. **Roberto Mina**, Maria Teresa Petrucci, Nicola Giuliani, Angelo Michele Carella, Mariella Genuardi, Tommaso Caravita di Toritto, Elena Ponticelli, Pellegrino Musto, Roberto Ria, Giovannino Ciccone, Elona Saraci, Massimo Offidani, Caterina Musolino, Rossella Troia, Anna Marina Liberati, Lorenzo De Paoli, Stelvio Ballanti, Fabrizio Esma, Piero Galieni, Michele Cavo, Concetta Conticello, Renato Zambello, Paolo Corradini, Patrizia Pregno, Antonio Palumbo, Pieter Sonneveld, Mario Boccardo, Sara Bringhen
Cardio-vascular toxicity in newly diagnosed, transplant-ineligible multiple myeloma patients treated with Carfilzomib, cyclophosphamide and dexamethasone: results from an integrated analysis of 3 phase I/II trials. Abstract e10 | 16th International Myeloma Workshop, March 1-4, 2017
7. Valeria Magarotto, Sara Bringhen, Massimo Offidani, Giulia Benevolo, Francesca Patriarca, **Roberto Mina**, Antonietta Pia Falcone, Lorenzo De Paoli, Giuseppe Pietrantuono, Silvia Gentili, Caterina Musolino, Nicola Giuliani, Annalisa Bernardini, Concetta Conticello, Stefano Pulini, Giovannino Ciccone, Vladimír Maisnar, Marina Ruggeri, Renato Zambello, Tommasina Guglielmelli, Antonio Ledda, Anna Marina Liberati, Vittorio Montefusco, Roman Hajek, Mario Boccardo and Antonio Palumbo.
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood 2016 127:1102-1108. ASH 2016
8. Chiara Cerrato, Francesca Gay, Maria Teresa Petrucci, Pellegrino Musto, Gianluca Gaidano, Massimo Offidani, Tommasina Guglielmelli, Marco Salvini, Francesca Patriarca, Elena Ponticelli, Gianpietro Semenzato, Francesco Di Raimondo, **Roberto Mina**, Nicola Cascavilla, Dina Ben Yehuda, Daniela Oddolo, Paolo Corradini, Lucio Catalano, Paolo Di Bartolomeo, Roman Hájek, Andrew Spencer, Mario Boccardo and Antonio Palumbo.
Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. Blood 2015 126:1974; ASH 2015
9. **Roberto Mina**, Alessandra Larocca, Massimo Offidani, Sara Bringhen, Tommaso Caravita, Valeria Magarotto, Lucia Pantani, Francesco Di Raimondo, Alberto Bosi, Iolanda D. Vincelli, Paola Tacchetti, Gianluca Gaidano, Sonia Grandi, Caterina Musolino, Chiara Cerrato, Ludek Pour, Monica Astolfi, Giuseppe Rossi, Fausto Rossini, Maria T. Petrucci, Roberto Ria, Annalisa Pezzi, Roman Hajek, Michele Cavo, Andrew Spencer, Mario Boccardo and Antonio Palumbo.
Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. Blood 2015 126:927; ASH 2015
10. S. Bringhen, D. Rossi, P. Sonneveld, A. Larocca, F. Gentilini, P. Galieni, A. Malfitano, R. Passera, M. Offidani, A.M. Liberati, **R. Mina**, G. Gaidano, M. Boccardo, P. Corradini, A. Palumbo.
Phase 1-2 clinical study of weekly carfilzomib in combination with cyclophosphamide and dexamethasone at diagnosis. Haematologica. EHA 2015

11. **R. Mina**, A. Larocca, M. Offidani, V. Magarotto, T. Caravita, R. van der Holt, F. Di Raimondo, A. Bosi, I.D. Vincelli, S. Croockewit, G. Gaidano, S. Grandi, C. Musolino, C. Cerrato, P. Ludk, M. Ruggeri, G. Rossi, F. Rossini, M.T. Petrucci, R. Ria, S. Zweegman, R. Hajek, A. Spencer, M. Boccadoro, P. Sonneveld, A. Palumbo.
Impact of complete response on progression-free survival and overall survival in newly diagnosed myeloma patients treated with autologous stem cell transplantation or conventional chemotherapy: results of a pooled analysis of 5 phase III trials. Clinical lymphoma myeloma and leukemia. IMW2015
12. Alessandra Larocca, Sara Bringhen, Roman Hajek, Maria Teresa Petrucci, Massimo Offidani, **Roberto Mina**, Vittorio Montefusco, Gabriele Aitoro, Claudia Cellini, Enrico Maria Pogliani, Lorenzo De Paoli, Marina Ruggeri, Laura Maracci, Oreste Villani, Chiara Nozzoli, Alessia La Fauci, Marta Chisini, Francesca Gay, Roberto Marasca, Stelvio Ballanti, Nicola Giuliani, Pellegrino Musto, Mario Boccadoro, Pieter Sonneveld and Antonio Palumbo.
The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy. Blood 2014 124:4740; ASH 2014
13. Alessandra Larocca, Vittorio Montefusco, Sara Bringhen, Davide Rossi, Claudia Crippa, **Roberto Mina**, Monica Galli, Magda Marcatti, Giacinto La Verde, Nicola Giuliani, Valeria Magarotto, Tommasina Guglielmelli, Delia Rota-Scalabrini, Paola Omedé, Alberto Santagostino, Ileana Baldi, Angelo Michele Carella, Mario Boccadoro, Paolo Corradini and Antonio Palumbo.
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood 2013 122:2799-2806. ASH 2013
14. Alessandra Larocca, Federica Cavallo, Valeria Magarotto, Massimo Offidani, Vincenzo Federico, Vanessa Innao, Antonietta Pia Falcone, Alessandra Romano, Tommaso Caravita, Davide Rossi, Giovanna Mansueto, **Roberto Mina**, Chiara Nozzoli, Giulia Benevolo, Tommasina Guglielmelli, Anna Marina Liberati, Daniele Derudas, Stefania Oliva, Fortunato Morabito, Angelo Michele Carella, Silvia Gentili, Elona Saraci, Maria Teresa Petrucci, Pieter Sonneveld, Mario Boccadoro and Antonio Palumbo.
Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age. Blood 2013 122:539; ASH 2013
15. Antonio Palumbo, Alessandra Larocca, Vittorio Montefusco, Davide Rossi, Angelo Michele Carella, **Roberto Mina**, Claudia Crippa, Mariella Sciacca, Monica Galli, Delia Rota Scalabrini, Magda Marcatti, Tommasina Guglielmelli, Nicola Giuliani, Giacinto La Verde, Ileana Baldi, Vittorio Emanuele Muccio, Mario Boccadoro and Paolo Corradini.
Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma. Blood 2012 120:446; ASH 2012

Book chapters

1. **Roberto Mina**, Alessandra Larocca, and Antonio Palumbo. *Haemopoietic diseases: leukaemias and myelomas.* In: Michel J-P, Beattie BL, Martin FC, Walston JD (Eds). *Oxford Textbook of Geriatric Medicine.* Oxford University Press: Oxford, 2017.

2. **Roberto Mina** and Antonio Palumbo. *Multiple Myeloma*. In: Wedding U., Audisio R. (Eds). *Management of Hematological Cancer in Older People*. Springer: London, 2015.

Organization and participation to national and international meetings

1. Multiple Myeloma and related malignancies, 4th edition. Bari, 8-10/11/2018. Speaker: How I treat very elderly patients with multiple myeloma.
2. Seminari di aggiornamento in ematologia neoplastica. Rionero in Vulture, 25/10/2018. Speaker: "Linee guida 2018 per la terapia del mieloma multiplo: best practice versus clinical trials".
3. "Under40 in Hematology", 17/18-11-2016. Speaker: "An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials."
4. ASH 2015 57th Annual Meeting. Orlando, FL, USA. Oral presentation. *Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients*. Blood 2015 126:927.
5. 8th Myeloma Practical Stage. Torino, 19-21.10.2015. Speaker: "Clinical cases on newly diagnosed multiple myeloma patients"
6. XVI International Myeloma Workshop, New Dehli, 1-4 March 2017. Oral presentation. *Cardio-vascular toxicity in newly diagnosed, transplant-ineligible multiple myeloma patients treated with Carfilzomib, cyclophosphamide and dexamethasone: results from an integrated analysis of 3 phase I/II trials*. Abstract e10
7. Myeloma Practical Stage. Torino, 27-28.09.2015. Speaker: "Clinical cases on newly diagnosed multiple myeloma patients"
8. 7th Myeloma Practical Stage. Torino, 27-28.09.2015. Speaker: "Consolidation and maintenance therapy in multiple myeloma?"
9. 7th Myeloma Practical Stage. Torino, 16-6-2014 al 17-6-2014. Speaker: "Clinical cases on newly diagnosed multiple myeloma patients"

Torino, January the 3rd, 2018

Dr. Roberto Mina

Autorizzo il trattamento dei dati personali ai sensi del GDPR e del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" ai fini di attività di Ricerca e Selezione del Personale e contatti lavorativi.

A handwritten signature in black ink, appearing to be 'Deby', written in a cursive style.